Company Active LTD

Company profile

Tailor Bio Ltd

Tailor Bio

Tailor Bio Ltd is a UK company with status active founded in 2019 based in East Midlands.

CRN
12229006
Founded
2019
Age
6

Overview

Legal name
TAILOR BIO LTD
Region
East Midlands
Registered address
KETTON SUITE, THE KING CENTRE, MAIN ROAD
BARLEYTHORPE
OAKHAM
RUTLAND
ENGLAND
LE15 7WD
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
04 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

26 Mar
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzUxMjgwNTMzOGFkaXF6a2N4

Published 26 Mar 2026 16:27

25 Mar
2026

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzUxMjUzODE0MWFkaXF6a2N4

Published 25 Mar 2026 13:59

21 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

26 Sep
2019

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2022
Age at first award
0 years

Projects

2022 Collaborative R&D Lead participant

Improving doxorubicin treatment in ovarian cancer

1 Apr 2022 to 30 Sep 2023

Awarded
£353,947
Total cost £505,638

**Public description:** Genetic tests are used to guide the treatment of many cancers, but each type of cancer requires a different test. The NHS is currently combining many genetic tests into a single test covering 500 genes. This is a major step forward and offers the opportunity to extend the testing to new drug response predictions and provide more tr...

2020 Collaborative R&D Lead participant

Whole genome sequencing of liquid biopsies to predict doxorubicin response in ovarian cancer

1 Sep 2020 to 31 Jul 2021

Awarded
£67,388
Total cost £96,268

Pinpoint Oncology is developing new genetic tests on DNA from tumours to take the guesswork out of treating the deadliest cancers. We use machine learning to find patterns in tumour DNA which can be used to predict a person's response to cancer drugs. Our current test uses a biopsy of a patient's tumour to predict if they will respond to a drug used to tr...

Product types

Collaborative R&D